

**B. PACKAGE LEAFLET**

## Package leaflet: Information for the user

### Vaxzevria suspension for injection COVID-19 Vaccine (ChAdOx1-S [recombinant])

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

#### **Read all of this leaflet carefully before the vaccine is given because it contains important information for you.**

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

#### **What is in this leaflet**

1. What Vaxzevria is and what it is used for
2. What you need to know before you are given Vaxzevria
3. How Vaxzevria is given
4. Possible side effects
5. How to store Vaxzevria
6. Contents of the pack and other information

#### **1. What Vaxzevria is and what it is used for**

Vaxzevria is used for preventing COVID-19 caused by the SARS-CoV-2 virus.

Vaxzevria is given to adults aged 18 years and older.

The vaccine causes the immune system (the body's natural defences) to produce antibodies and specialised white blood cells that work against the virus, so giving protection against COVID-19. None of the ingredients in this vaccine can cause COVID-19.

#### **2. What you need to know before you are given Vaxzevria**

##### **The vaccine must not be given:**

- If you are allergic to the active substance or any of the other ingredients of this vaccine (listed in section 6).
- If you have had a blood clot occurring at the same time as having low levels of blood platelets (thrombosis with thrombocytopenia syndrome, TTS) after receiving Vaxzevria.
- If you have a previous diagnosis of capillary leak syndrome (a condition causing fluid leakage from small blood vessels).

#### **Warnings and precautions**

Talk to your doctor, pharmacist or nurse before you are given Vaxzevria:

- If you have ever had a severe allergic reaction after any other vaccine injection or after you were given Vaxzevria in the past;
- If you have ever fainted following any needle injection;
- If you have a severe infection with a high temperature (over 38°C). However, you can have your vaccination if you have a mild fever or upper airway infection like a cold;
- If you have a problem with bleeding or bruising, or if you are taking an anticoagulant medicine (to prevent blood clots);

- If your immune system does not work properly (immunodeficiency) or you are taking medicines that weaken the immune system (such as high-dose corticosteroids, immunosuppressants or cancer medicines).

If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before you are given the vaccine.

As with any vaccine, the 2-dose vaccination course of Vaxzevria may not fully protect all those who receive it. It is not known how long you will be protected for. Currently there are limited data on the efficacy of Vaxzevria in individuals aged 55 and older.

#### *Blood disorders*

Very rare blood clots in combination with low level of blood platelets, in some cases together with bleeding, has been observed following vaccination with Vaxzevria. This included some severe cases with blood clots in different or unusual locations (e.g. brain, bowel, liver, spleen) and excessive clotting or bleeding throughout the body. The majority of these cases occurred within the first three weeks following vaccination and occurred mostly in women under 60 years of age. Some cases had a fatal outcome.

Seek immediate medical attention if you develop shortness of breath, chest pain, leg swelling, leg pain or persistent abdominal pain following vaccination (see section 4).

Also, seek immediate medical attention if you experience after a few days severe or persistent headaches, blurred vision, confusion or seizures (fits) after vaccination, or experience skin bruising or pinpoint round spots beyond the site of vaccination which appears after a few days (see section 4).

#### *Capillary leak syndrome*

Very rare cases of capillary leak syndrome (CLS) have been reported following vaccination with Vaxzevria. Some affected patients had a previous diagnosis of CLS. CLS is a serious, potentially fatal condition causing fluid leakage from small blood vessels (capillaries) resulting in rapid swelling of the arms and legs, sudden weight gain and feeling faint (low blood pressure). Seek immediate medical attention if you develop these symptoms in the days following vaccination.

#### *Neurological events*

Seek immediate medical attention if you develop weakness and paralysis in the extremities that can progress to the chest and face (Guillain-Barré syndrome). This has been reported very rarely after vaccination with Vaxzevria.

### **Children and adolescents**

Vaxzevria is not recommended for children aged below 18 years. Currently there is not enough information available on the use of Vaxzevria in children and adolescents younger than 18 years of age.

### **Other medicines and Vaxzevria**

Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take, any other medicines or vaccines.

### **Pregnancy and breastfeeding**

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before you receive this vaccine.

### **Driving and using machines**

Some of the side effects of Vaxzevria listed in section 4 (Possible side effects) may temporarily reduce your ability to drive and use machines. If you feel unwell after vaccination, do not drive or use machines. Wait until any effects of the vaccine have worn off before you drive or use machines.

### **Vaxzevria contains sodium and alcohol (ethanol)**

This medicine contains less than 1 mmol sodium (23 mg) per 0.5 ml dose, that is to say essentially 'sodium-free'.

This medicine contains 2 mg of alcohol (ethanol) per 0.5 ml dose. The small amount of alcohol in this medicine will not have any noticeable effects.

### **3. How Vaxzevria is given**

Vaxzevria is given as an injection of 0.5 ml into a muscle (usually in the upper arm).

During and after each injection of the vaccine, your doctor, pharmacist or nurse will watch over you for around 15 minutes to monitor for signs of an allergic reaction.

**You will receive 2 injections** of Vaxzevria. The second injection can be given between 4 and 12 weeks after the first injection. You will be told when you need to return for your second injection.

When Vaxzevria is given for the first injection, the second injection to complete the vaccination course should also be with Vaxzevria.

### **If you miss an appointment for your second injection of Vaxzevria**

If you forget to go back at the scheduled time, ask your doctor, pharmacist or nurse for advice. It is important that you return for your second injection of Vaxzevria. If you miss a scheduled injection, you may not be fully protected against COVID-19.

### **4. Possible side effects**

Like all medicines, this vaccine can cause side effects, although not everybody gets them.

In clinical studies, most side effects were mild to moderate in nature and resolved within a few days. Fewer side effects were reported after the second dose.

After vaccination, you may have more than one side effect at the same time (for example, muscle/joint aches, headaches, chills and generally feeling unwell). If any of your symptoms are persistent, please seek advice from your doctor, pharmacist or nurse.

Blood clots in combination with low levels of blood platelets (thrombosis with thrombocytopenia syndrome, TTS) have been reported very rarely, see section 2.

**Get medical attention immediately** if within three weeks of vaccination you get any of the following symptoms:

- experience a severe or persistent headache, blurred vision, confusion or seizures (fits)
- develop shortness of breath, chest pain, leg swelling, leg pain or persistent abdominal pain
- notice unusual skin bruising or pinpoint round spots beyond the site of vaccination

**Get urgent medical attention** if you get symptoms of a severe allergic reaction. Such reactions may include a combination of any of the following symptoms:

- feeling faint or light-headed
- changes in your heartbeat
- shortness of breath
- wheezing
- swelling of your lips, face, or throat
- hives or rash
- nausea or vomiting
- stomach pain.

**The following side effects may occur with Vaxzevria:**

**Very Common** (may affect more than 1 in 10 people)

- tenderness, pain, warmth, itching, or bruising where the injection is given
- feeling tired (fatigue) or generally feeling unwell
- chills or feeling feverish
- headache
- feeling sick (nausea)
- joint pain or muscle ache

**Common** (may affect up to 1 in 10 people)

- swelling or redness where the injection is given
- fever ( $\geq 38^{\circ}\text{C}$ )
- being sick (vomiting) or diarrhoea
- low level of blood platelets
- pain in legs or arms
- flu-like symptoms, such as high temperature, sore throat, runny nose, cough and chills
- physical weakness or lack of energy

**Uncommon** (may affect up to 1 in 100 people)

- sleepiness or feeling dizzy
- abdominal pain or decreased appetite
- enlarged lymph nodes
- excessive sweating, itchy skin, rash or hives
- sleepiness or deep unresponsiveness and inactivity

**Very Rare** (may affect up to 1 in 10,000 people)

- blood clots often in unusual locations (e.g. brain, bowel, liver, spleen) in combination with low level of blood platelets

**Not known** (cannot be estimated from the available data)

- severe allergic reaction (anaphylaxis)
- hypersensitivity
- rapid swelling under the skin in areas such as the face, lips, mouth and throat (which may cause difficulty in swallowing or breathing)
- capillary leak syndrome (a condition causing fluid leakage from small blood vessels)

**Reporting of side effects**

**If you get any side effects, talk to your doctor, pharmacist or nurse.** This includes any possible side effects not listed in this leaflet. You can also report side effects directly via [the national reporting system listed in Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

**5. How to store Vaxzevria**

Keep this medicine out of the sight and reach of children.

Your doctor, pharmacist or nurse is responsible for storing this vaccine and disposing of any unused product correctly. The following information about storage, expiry, use and handling as well as disposal is intended for healthcare professionals.

Do not use this vaccine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.

Store in a refrigerator ( $2^{\circ}\text{C} - 8^{\circ}\text{C}$ ).

Do not freeze.

Keep vials in outer carton in order to protect from light.

From the time of vial opening (first needle puncture) use within 6 hours when stored at temperatures up to 30°C. After this time, the vial must be discarded. Do not return it to the refrigerator. Alternatively, an opened vial may be stored in a refrigerator (2°C – 8°C) for a maximum of 48 hours if it is immediately returned to the refrigerator following each puncture.

Discard the vial if the suspension is discoloured or particles are observed. Do not shake.

## **6. Contents of the pack and other information**

### **What Vaxzevria contains**

One dose (0.5 ml) contains:

Chimpanzee Adenovirus encoding the SARS-CoV-2 Spike glycoprotein ChAdOx1-S\*, not less than  $2.5 \times 10^8$  infectious units

\*Produced in genetically modified human embryonic kidney (HEK) 293 cells and by recombinant DNA technology.

This product contains genetically modified organisms (GMOs).

The other excipients are L-histidine, L-histidine hydrochloride monohydrate, magnesium chloride hexahydrate, polysorbate 80 (E 433), sucrose, disodium edetate (dihydrate), water for injections (see section 2 “Vaxzevria contains sodium and alcohol”).

### **What Vaxzevria looks like and contents of the pack**

Suspension for injection (injection). The suspension is colourless to slightly brown, clear to slightly opaque.

Pack sizes:

- 8-dose multidose vial (4 ml) with stopper (elastomeric with aluminium overseal) in a pack of 10 vials. Each vial contains 8 doses of 0.5 ml.
- 10-dose multidose vial (5 ml) with stopper (elastomeric with aluminium overseal) in a pack of 10 vials. Each vial contains 10 doses of 0.5 ml.

Not all pack sizes may be marketed.

### **Marketing Authorisation Holder**

AstraZeneca AB  
SE-151 85 Södertälje  
Sweden

### **Manufacturer**

AstraZeneca Nijmegen B.V.  
Lagelandseweg 78  
Nijmegen, 6545CG  
Netherlands

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

#### **België/Belgique/Belgien**

AstraZeneca S.A./N.V.  
Tel: Tel: +32 2 808 53 06

#### **Lietuva**

UAB AstraZeneca Lietuva  
Tel: +370 5 2141423

#### **България**

АстраЗенека България ЕООД

#### **Luxembourg/Luxemburg**

AstraZeneca S.A./N.V.

Тел.: +359 (2) 90 60 798

Tél/Tel: +352 2 7863166

### **Česká republika**

AstraZeneca Czech Republic s.r.o.  
Tel: +420 228 882 054

### **Magyarország**

AstraZeneca Kft.  
Tel.: +36 80 180 007

### **Danmark**

AstraZeneca A/S  
Tlf: +45 89 87 04 78

### **Malta**

Associated Drug Co. Ltd  
Tel: +356 2277 8134

### **Deutschland**

AstraZeneca GmbH  
Tel: 0800 22 88 660 (gebührenfrei)

### **Nederland**

AstraZeneca BV  
Tel: 0800 70 11 (gratis)  
+31 79 363 2222

### **Eesti**

AstraZeneca  
Tel: +372 6549 600

### **Norge**

AstraZeneca AS  
Tlf: +47 23 96 23 13

### **Ελλάδα**

AstraZeneca A.E.  
Τηλ: +30 211 1983792

### **Österreich**

AstraZeneca Österreich GmbH  
Tel: +43 1 711 31 0

### **España**

AstraZeneca Farmacéutica Spain, S.A.  
Tel: +34 93 220 20 14

### **Polska**

AstraZeneca Pharma Poland Sp. z o.o.  
Tel.: +48 22 104 60 80

### **France**

AstraZeneca  
Tél: 0 800 08 92 44 (numéro vert)

### **Portugal**

AstraZeneca Produtos Farmacêuticos, Lda.  
Tel: +351 30 880 17 68

### **Hrvatska**

AstraZeneca d.o.o.  
Tel: +385 1 4628 000

### **România**

AstraZeneca Pharma SRL  
Tel: +40 31 630 03 18

### **Ireland**

AstraZeneca Pharmaceuticals (Ireland) DAC  
Tel: 1800 812456 (toll free)

### **Slovenija**

AstraZeneca UK Limited  
Tel: +386 1 60 03 197

### **Ísland**

Vistor hf.  
Sími: +354 519 3643

### **Slovenská republika**

AstraZeneca AB, o.z.  
Tel: +421 2 3321 5491

### **Italia**

AstraZeneca S.p.A.  
Tel: +39 02 9801 4221

### **Suomi/Finland**

AstraZeneca Oy  
Puh/Tel: +358 94 24 55072

### **Κύπρος**

Αλέκτωρ Φαρμακευτική Λτδ  
Τηλ: +357 22090050

### **Sverige**

AstraZeneca AB  
Tel: +46 3 130 11 892

### **Latvija**

SIA AstraZeneca Latvija  
Tel: +371 68688132

### **United Kingdom (Northern Ireland)**

AstraZeneca UK Ltd  
Tel: +44 8000 541 028

### **This leaflet was last revised in**

This medicine has been given ‘conditional approval’. This means that there is more evidence to come about this medicine.

The European Medicines Agency will review new information on this medicine at least every year and this leaflet will be updated as necessary.

### **Other sources of information**

Scan the QR code with a mobile device to get **this information in different languages**.



[www.azcovid-19.com](http://www.azcovid-19.com)

Detailed information on this medicine is available on the European Medicines Agency web site:  
<http://www.ema.europa.eu>

This leaflet is available in all EU/EEA languages on the European Medicines Agency website.

---

The following information is intended **for healthcare professionals only**:

For storage and disposal, see section 5 “How to store Vaxzevria”.

### **Traceability**

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

### **Handling instructions and administration**

This vaccine should be handled by a healthcare professional using aseptic technique to ensure the sterility of each dose.

The vaccine should be inspected visually for particulate matter and discolouration prior to administration. Vaxzevria is a colourless to slightly brown, clear to slightly opaque suspension. Discard the vial if the suspension is discoloured or visible particles are observed. Do not shake. Do not dilute the suspension.

The vaccine should not be mixed in the same syringe with any other vaccines or medicinal products.

The Vaxzevria vaccination course consists of two separate doses of 0.5 ml each. The second dose should be administered between 4 and 12 weeks after the first dose. Individuals who have received the first dose of Vaxzevria should receive the second dose of the same vaccine to complete the vaccination course.

Each vaccine dose of 0.5 ml is withdrawn into a syringe for injection to be administered intramuscularly, preferably in the deltoid muscle of the upper arm. Use a new needle for administration, when possible.



It is normal for liquid to remain in the vial after withdrawing the final dose. An additional overfill is included in each vial to ensure that 8 doses (vial of 4 ml) or 10 doses (vial of 5 ml) of 0.5 ml can be delivered. Do not pool excess vaccine from multiple vials. Discard any unused vaccine.

### **Disposal**

Any unused vaccine or waste material should be disposed of in compliance with the local guidance for pharmaceutical waste. Potential spills should be disinfected with agents with viricidal activity against adenovirus.